



Grünenthal GmbH

EUR 400,000,000 3.625% Senior Secured Notes due 2026

XS2337064856 and XS2337065077

EUR 550,000,000 4.125% Senior Secured Notes due 2028

XS2337703537 and XS2337703610

EUR 300,000,000 6.750% Senior Secured Notes due 2030

XS2615562274 and XS2615563082

Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration

Aachen, Germany and Tokyo, Japan, 2 August 2023 – Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company and Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the successful completion of a deal to enter into a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio.

The portfolio comprises 13 brands across six therapeutic areas primarily focused on pain management, including Abstral® and PecFent® for breakthrough cancer pain, Moventig® for opioid-induced constipation, and Adcal-D3® for osteoporosis. All products will continue to be marketed through affiliates in seven major European countries and through a network of partners in various additional territories worldwide.

Grünenthal owns a 51 percent majority share in the Joint Venture Collaboration, while Kyowa Kirin owns a 49 percent share. Grünenthal intends to fully acquire the remaining 49 percent share via exercising an option at the beginning of 2026.

For further information, please refer to the just published press release or contact:

Anna Carduck
Creditor Relations

Phone: +49 241 569 3767
creditor-relations@grunenthal.com

Grünenthal GmbH
52099 Aachen | Germany
www.grunenthal.com